Breaking News
Sort by:
Top Post
Experimental Cancer Drug May Slow Inflammation Linked to Heart Disease
An experimental drug already tested as a potential treatment for cancer, lung, and Alzheimer’s disease […]
Kuria Therapeutics Completes FDA Pre-IND Consultation for Topical Nrf2 Activator for Corneal Endothelial Disease
Kuria Therapeutics, a pharmaceutical company developing novel ophthalmic and dermal therapeutics, is pleased to announce […]
GeminiBio Appoints Industry Veteran Cory Stevenson as Executive Chairman
Gemini BioProducts (GeminiBio), a portfolio company of BelHealth Investment Partners, a Florida-based healthcare private equity […]
Vanda Pharmaceuticals Appoints Dr. Tage Honoré to its Board of Directors
Vanda Pharmaceuticals today announced the appointment of Dr Tage Honoré, Ph.D., D.Sc. to its Board […]
Leap Therapeutics Provides Update on BeiGene Option Agreement for DKN-01
Leap Therapeutics, a biotechnology company focused on developing targeted and immuno-oncology therapeutics, today announced that […]
Phase 3 Study Shows XTANDI® (enzalutamide) plus Leuprolide Significantly Improves Metastasis-Free Survival in Men with Non-Metastatic Prostate Cancer
Pfizer and Astellas Pharma have announced positive topline results from the Phase 3 EMBARK trial […]
Matrivax Initiates Phase 1 Clinical Development of MVX01, a Novel Pneumococcal Vaccine Candidate
Vaccine development company Matrivax announces the start of its Phase 1 clinical study to assess […]
Invitae Appoints Dr. W. Michael Korn as Chief Medical Officer for Oncology
Invitae, a leading medical genetics company, has announced the appointment of Dr. W. Michael Korn, […]
Synthego Introduces CRISPR Discovery Partners to Streamline CRISPR-Driven Drug Discovery Research
Synthego, a leading genome engineering solutions provider, announced today the launch of its service partner […]
Synaffix Announces Expansion of ADC Collaboration with MacroGenics
Synaffix, a biotechnology company focused on commercializing its clinical-stage platform technology for the development of […]
Mitsubishi Tanabe Pharma America Announces More Than 10,000 People with ALS Treated with RADICAVA ORS® and/or RADICAVA®
Mitsubishi Tanabe Pharma America today announced that more than 10,000 people with amyotrophic lateral sclerosis […]
- Eloxx Pharmaceuticals Announces Final Data Assessment from Phase 2 Combination Clinical Trial of ELX-02 in Class 1 Cystic Fibrosis Patients Read more
- Verge Genomics Announces Positive Safety and Tolerability Data from the Phase 1 Clinical Trial of VRG50635, a Potential Best-in-Class Therapeutic for All Forms of ALS Read more
- DEM BioPharma Appoints Wendy Young, Ph.D., to Scientific Advisory Board Read more
- Confo Therapeutics Enters into Research Collaboration for GPCR-Targeting Antibody Discovery with AbCellera Read more
- Vyriad Announces Expansion of T-Cell Lymphoma Trial at Mayo Clinic Read more